Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Xeris Biopharma Q4 2025 Earnings Call - Financial self-sustainability and 30%+ revenue growth guide for 2026
Xeris closed 2025 with a clean break from the financing treadmill, reporting full-year revenue of $291.8 million, adjusted EBITDA of $59.4 million and net income for the year. Management calls 2025 tr...
- Full-year 2025 revenue was $291.8 million, up 44% year-over-year; Q4 revenue was $85.8 million, up 43% y/y.
- Xeris reported adjusted EBITDA of $59.4 million for 2025 and delivered net income on a full-year basis for the first time.
- Management says Xeris achieved financial self-sustainability, enabling internal funding for the pipeline and commercial expansion.
- +15 more takeaways
Norwegian Cruise Line Holdings Q4 2025 Earnings Call - New CEO flags execution failures, trims 2026 yield outlook to flat
John Chidsey, who joined the board last year and became CEO in the last two weeks, laid out a blunt diagnosis: strategy is sound, execution is not. Q4 and full-year 2025 results showed healthy margin ...
- New CEO John Chidsey has been on the job only a few weeks, and his top priorities are fixing execution, driving accountability, reducing leverage, and improving return on invested capital.
- Q4 2025 net yields grew 3.8%, full-year 2025 net yields rose 2.4% versus prior year.
- Q4 Adjusted EBITDA was $564 million, full-year Adjusted EBITDA was $2.73 billion, up 11% year-over-year; Adjusted Operational EBITDA margin improved to 37.1% (+160 bps).
- +12 more takeaways
Compugen Q4 2025 Earnings Call - AstraZeneca Monetization Buys Runway into 2029 While Preserving Majority Royalties
Compugen used a small, strategic monetization of future rilvegostomig royalties to secure $65 million upfront from AstraZeneca, extending its cash runway into 2029 and adding a $25 million near-term m...
- Compugen monetized a small portion of future rilvegostomig royalties to AstraZeneca for $65 million upfront, extending cash runway into 2029 assuming no further cash inflows.
- Deal added a $25 million milestone tied to BLA acceptance, and increased total remaining milestones tied to rilvegostomig to up to $195 million from $170 million previously.
- Company retains the majority of its royalty interest in rilvegostomig, remaining eligible for mid-single-digit tiered royalties on future sales.
- +12 more takeaways
Yatsen Q4 and Full Year 2025 Earnings Call - Skincare-Led Recovery Narrows Losses, Non-GAAP Turnaround
Yatsen closed 2025 with a clear, R&D-fueled recovery: revenue returned to robust growth and profitability crept back into the picture, driven almost entirely by skincare. Q4 revenue rose 20.1% year ov...
- Total net revenues for Q4 2025 rose 20.1% year over year to RMB 1.38 billion, matching prior guidance and outpacing industry growth.
- Full-year 2025 revenue grew 26.7% to RMB 4.3 billion, reversing the 2024 decline and signaling a broader recovery in the business.
- Skincare was the engine, with Q4 skincare revenue up 51.9% year over year, and full-year skincare revenue up 63.5%; skincare accounted for 61.1% of Q4 revenues and 53% for the full year.
- +13 more takeaways
Smith+Nephew Q4 & FY2025 Earnings Call - Product-led growth, margin expansion and Integrity buy to accelerate shoulders
Smith+Nephew closed 2025 with a clean set of results: underlying revenue up 5.3%, trading margin expanded 160 basis points to 19.7%, and free cash flow jumped to $840 million, enabling a $500 million ...
- FY2025 underlying revenue grew 5.3%, with all three business units above 5%, and Q4 revenue of $1.7 billion up 6.2% underlying (4.5% on an average daily sales basis).
- Trading margin expanded 160 basis points to 19.7% for 2025, driven by price, revenue leverage and productivity; gross margin rose to 70.9%.
- Free cash flow surged to $840 million, up 52.5% year on year, enabling completion of a $500 million share buyback in H2 2025. Net debt finished at $2.76 billion with leverage around 1.7x.
- +12 more takeaways
Endeavour Silver Q4 2025 Earnings Call - Kolpa, Terronera drove 48% production jump; $350M convertible backs Pitarrilla advance
Endeavour closed a transformational 2025: Kolpa was acquired, Terronera reached commercial production in October, and the company raised $350 million via a convertible debt to fund Pitarrilla. Those m...
- 2025 was transformational: Kolpa acquired in May, Terronera reached commercial production October 1, and Bolanitos was sold (closed Jan 15).
- Production jumped to 11 million ounces silver equivalent in 2025, a 48% increase versus 2024, with Q4 output about 2 million ounces of silver and 14,000 ounces of gold (nearly 4 million silver equivalent ounces in Q4).
- Record 2025 revenue of $468 million, up 115% year-over-year; mine operating earnings were $83 million and mine operating cash flow before taxes was $156 million. Cash position at December 31 was $215 million.
- +12 more takeaways
Sunstone Hotel Investors Fourth Quarter 2025 Earnings Call - Andaz Miami Beach Momentum Boosts RevPAR, Board Reauthorizes $500M Buyback
Sunstone closed 2025 on a stronger-than-expected note, driven by resort outperformance and the late-year contribution from the newly renovated Andaz Miami Beach. Q4 total RevPAR grew 7.4% (12.5% inclu...
- Q4 2025 results beat expectations, with total RevPAR growth of 7.4% and 12.5% including Andaz Miami Beach.
- Andaz Miami Beach is the clear operational driver, contributing ~540 basis points to rooms RevPAR and ~510 basis points to total RevPAR in Q4; YTD occupancy above 80% at a mid-$500 rate and RevPAR near $475.
- Company issued full-year 2026 guidance: rooms RevPAR +4% to +7% (to $234-$241) and total RevPAR +3.5% to +6.5% (to $385-$396), with Andaz contributing ~400 basis points at the midpoint.
- +12 more takeaways
Delek Logistics Partners Q4 2025 Earnings Call - Record 2025 EBITDA, sour gas ramp is the hinge for 2026 upside
Delek Logistics closed 2025 with a full year record Adjusted EBITDA of $536 million and a record fourth quarter Adjusted EBITDA of approximately $142 million. Management is pitching 2026 EBITDA in a $...
- Delek Logistics reported record full year 2025 Adjusted EBITDA of $536 million, driven by acquisitions and operations across gas, crude, and water businesses.
- Fourth quarter Adjusted EBITDA was about $142 million, up from $114 million a year earlier and $6 million above the prior quarter record.
- Distributable cash flow as adjusted for Q4 was $73 million, with an adjusted DCF coverage ratio of approximately 1.22 times.
- +12 more takeaways
BlackRock TCP Capital Corp. Q4 2025 Earnings Call - NAV down 19% as six investments drove bulk of markdowns
BlackRock TCP Capital reported a difficult Q4 and full-year 2025, with adjusted NII for the year falling to $1.22 per share from $1.52 in 2024 and annualized NAI ROE sliding to 12.3% from 14.5%. NAV p...
- NAV fell 19% to $7.07 at year-end from $8.71 at quarter-end, matching the midpoint of the pre-announced range from January 23.
- Six investments accounted for roughly 67% of the NAV decline, contributing about $1.11 per share of the drop.
- Largest individual markdowns: Edmentum $0.38 per share (23% of the NAV decline), Razor $0.24 (15%) now written to zero, SellerX $0.22 (13%), Renovo $0.15, Hylan $0.06, and InMobi $0.06.
- +12 more takeaways
TransAlta Q4 2025 Earnings Call - Keephills data center MOU positions company to capture up to 1 GW of new demand
TransAlta closed 2025 with headline Adjusted EBITDA of CAD 1.1 billion and reported full‑year free cash flow of roughly CAD 514 million, while naming CFO Joel Hunter as incoming CEO and pacing a slate...
- Strategic MOU inked with CPP Investments and Brookfield for Keephills, giving TransAlta exclusive site and power provider status for an initial long‑term PPA of ~230 MW and an evaluation path to aggregate up to 1 GW of demand.
- Centralia Unit Two conversion to natural gas under a long‑term tolling agreement with Puget Sound Energy, ~700 MW contracted to 2044; estimated conversion capex ~USD/CAD 600 million and targeted commercial operation late 2028, with FID aimed for early 2027.
- Full‑year Adjusted EBITDA reported at CAD 1.1 billion; management later aggregated free cash flow at roughly CAD 514 million for 2025 (the call also referenced CAD 450 million earlier), and said FCF was above the midpoint of guidance.
- +12 more takeaways